TransMedics named as short idea with $0 target by Scorpion Capital

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients.” The short-seller adds in its report, in which it calls out a price target of $0 for the stock, that the firm is “shortly filing a Citizen Petition with the FDA requesting suspension of PMA (Premarket Approval) of TransMedics Organ Care System, in conjunction with a public letter to members of Congress probing abuses in the US organ transplant system.”